Aprea Therapeutics Reports Third Quarter 2019 Financial Results
Third quarter 2019 Corporate Update:
Earlier this month, the Company announced that it will present updated data from two Phase 1b/2 clinical studies at the 61st
- “Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)”; and
- “APR-246 combined with Azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). A phase 2 study by Groupe Francophone des Myélodysplasies (GFM)”
The Company will host a Clinical Update Meeting and Webcast on
Initial Public Offering
Third Quarter Financial Results
- Cash and cash equivalents: As of September 30, 2019, prior to completing its IPO on
October 7, 2019, Aprea had $52.3 million of cash and cash equivalents compared to $65.7 million of cash and cash equivalents as of December 31, 2018. In October 2019, the Company completed the sale of 6,516,667 shares of common stock in an initial public offering resulting in gross proceeds of approximately $97.75 million. The Company believes its cash and cash equivalents as of September 30, 2019 along with the proceeds received from its initial public offering will be sufficient to meet its current projected operating requirements into 2023.
- Research and Development (R&D) expenses: R&D expenses were $4.9 million for the quarter ended September 30, 2019, compared to $2.3 million for the comparable period in 2018. The increase in R&D expenses was primarily related to the advancement of the Company’s lead product candidate, APR-246. In Q1 2019 the Company commenced a pivotal Phase 3 clinical trial of APR-246 with azacitidine for frontline treatment of TP53 mutant MDS which is supported by two ongoing Phase 1b/2 investigator initiated trials, one in the U.S. and one in
France, testing APR-246 with azacitidine as frontline treatment in TP53 mutant MDS and AML patients.
- General and Administrative (G&A) expenses: G&A expenses were $2.3 million for the quarter ended September 30, 2019, compared to $0.6 million for the comparable period in 2018. The increase in G&A expenses was primarily due to increased professional fees of approximately
$1.3 millionassociated with preparation for the Company’s IPO, which was completed in October 2019, as well as increased personnel costs of $0.3 million.
- Net loss: Net loss was $6.2 million for the quarter ended September 30, 2019, compared to a net loss of $3.1 million for the quarter ended September 30, 2018.
About Aprea Therapeutics, Inc.
The Company may use, and intends to use, its investor relations website at www.ir.aprea.com as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials, regulatory submissions and projected cash position. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Registration Statement on Form S-1 (File No. 333-233662) and our Quarterly Report on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Source: Aprea Therapeutics
Sr. Vice President and Chief Financial Officer
Vice President of Business Development
Condensed Consolidated Balance Sheets
|Cash and cash equivalents||$||52,334,102||$||65,675,931|
|Deferred offering cost||4,070,690||—|
|Prepaid expenses and other current assets||339,814||322,146|
|Total current assets||56,744,606||65,998,077|
|Property and equipment, net||31,032||24,450|
|Right of use lease asset||560,318||—|
|Other noncurrent assets||102||111|
|Liabilities, Convertible Preferred Stock and Stockholders’ Deficit|
|Total current liabilities||9,584,321||4,868,109|
|Commitments and contingencies|
|Convertible preferred stock:|
|Series A convertible preferred stock, $0.001 par value; 612,446 shares issued and outstanding at September 30, 2019 and December 31, 2018 (liquidation preference of $6,483,044 at September 30, 2019)||6,483,044||6,483,044|
|Series B convertible preferred stock, $0.001 par value; 7,235,969 shares issued and outstanding at September 30, 2019 and December 31, 2018 (liquidation preference of $62,288,856 at September 30, 2019)||49,742,942||49,742,942|
|Series C convertible preferred stock, $0.001 par value; 5,179,877 and 4,712,698 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively (liquidation preference of $66,451,815 at September 30, 2019)||61,963,007||56,364,645|
|Total convertible preferred stock||118,188,993||112,590,631|
|Stockholders’ equity (deficit):|
|Common stock, par value $0.001 at September 30, 2019 and $0.11 at December 31, 2018; 1,181,733 and 1,155,366, shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively||1,182||127,091|
|Additional paid‑in capital||20,346,849||19,666,588|
|Accumulated other comprehensive loss||(13,688,166||)||(8,761,325||)|
|Total stockholders’ deficit||(70,795,660||)||(51,436,102||)|
|Total liabilities, convertible preferred stock and stockholders’ deficit||$||57,336,058||$||66,022,638|
Condensed Consolidated Statements of Operations and Comprehensive Loss
|Three Months Ended September 30,
||Nine Months Ended September 30,
|Research and development||$||4,910,409||$||2,307,022||$||12,908,679||$||9,799,811|
|General and administrative||2,307,946||623,702||4,655,861||1,790,222|
|Total operating expenses||7,218,355||2,930,724||17,564,540||11,590,033|
|Other income (expense):|
|Foreign currency gain (loss)||975,034||(207,542||)||2,591,008||741,616|
|Total other income (expense)||968,936||(207,538||)||2,577,471||741,432|
|Other comprehensive loss:|
|Foreign currency translation||(2,940,174||)||65,800||(4,926,841||)||(1,110,408||)|
|Total comprehensive loss||(9,189,593||)||(3,072,462||)||(19,913,910||)||(11,959,009||)|
|Net loss per share attributable to common stockholders, basic and diluted||$||(5.29||)||$||(2.72||)||$||(12.72||)||$||(9.40||)|
|Weighted average basic and diluted shares of common stock outstanding||1,181,726||1,154,573||1,178,206||1,154,264|
Source: Aprea Therapeutics